DHS 157.61(4)(b)(b) The written directive shall contain the patient or human research subject’s name and all of the following information: DHS 157.61(4)(b)1.1. For the administration of a dosage of a radioactive drug, the name, dosage and administration route of the radioactive drug. DHS 157.61(4)(b)2.2. For each anatomically distinct treatment site exposed to gamma stereotactic radiosurgery, total dose, treatment site and number of target settings per treatment. DHS 157.61(4)(b)3.3. For teletherapy, the total dose, dose per fraction, number of fractions, treatment site and overall treatment period. DHS 157.61(4)(b)4.4. For high dose rate remote afterloading brachytherapy: the radionuclide, treatment site, dose per fraction, number of fractions and total dose. DHS 157.61(4)(b)5.a.a. Before implantation, the written directive shall include the treatment site, the radionuclide, and the total source strength. DHS 157.61(4)(b)5.b.b. After implantation but before the patient leaves the post-treatment recovery area, the written directive shall include the treatment site, the number of sources implanted, the total source strength implanted, and the date. DHS 157.61(4)(b)6.6. For all other brachytherapy including low dose rate, medium dose rate and pulsed dose rate afterloaders: DHS 157.61(4)(b)6.a.a. Before implantation, the written directive shall include the treatment site, radionuclide, and dose. DHS 157.61(4)(b)6.b.b. After implantation but before completion of the procedure, the written directive shall include the radionuclide, treatment site, number of sources, and total source strength and exposure time (or the total dose), and date. DHS 157.61(5)(5) Procedures for administrations requiring a written directive. DHS 157.61(5)(a)(a) For any administration requiring a written directive, a licensee shall develop, implement and maintain written procedures to help ensure both of the following: DHS 157.61(5)(a)1.1. The patient’s or human research subject’s identity is verified by more than one method before each administration. DHS 157.61(5)(a)2.2. Each administration is performed according to the provisions of a written directive. DHS 157.61(5)(b)(b) The procedures required by par. (a) shall address all of the following items that are applicable for the licensee’s use of radioactive material: DHS 157.61(5)(b)1.1. Verifying the identity by more than one method of the patient or human research subject. DHS 157.61(5)(b)2.2. Verifying that the specific details of the administration are under the treatment plan, if applicable, and the written directive. DHS 157.61(5)(b)4.4. Verifying that any computer-generated dose calculations are correctly transferred into the consoles of therapeutic medical units authorized by s. DHS 157.67 or 157.70. DHS 157.61(5)(b)6.6. Determining, for permanent implant brachytherapy, within 60 calendar days from the date the implant was performed, the total source strength administered outside of the treatment site compared to the total source strength documented in the post-implantation portion of the written directive, unless a written justification of patient unavailability is documented. DHS 157.61(6)(6) Suppliers for sealed sources or devices for medical use. For medical use, a licensee may only use the following: DHS 157.61(6)(a)(a) Sealed sources or devices manufactured, labeled, packaged and distributed under a license issued under subch. II or the equivalent requirements of the NRC or another agreement state. DHS 157.61(6)(b)(b) Teletherapy sources manufactured and distributed under a license issued under subch. II or the equivalent requirements of the NRC or another agreement state. DHS 157.61(6)(c)(c) Sealed sources or devices non-commercially transferred from a medical licensee. DHS 157.61(7)(7) Training for radiation safety officer and associate radiation safety officer.. Except as provided in sub. (10), a licensee shall ensure that an individual fulfilling the responsibilities of the radiation safety officer, or an individual assigned duties and tasks as an associate radiation safety officer as provided in this section, is an individual who has training in radiation safety, regulatory issues and emergency procedures for the types of use for which a licensee seeks approval. This training requirement may be satisfied by completing training that is supervised by a radiation safety officer, associate radiation safety officer, authorized medical physicist, authorized nuclear pharmacist or authorized user, as appropriate, who is authorized for the type of use for which the licensee is seeking approval. A licensee shall also require the radiation safety officer or an associate radiation safety officer to be a person who meets any of the following requirements: DHS 157.61(7)(a)(a) Is certified by a specialty board whose certification process has been recognized by the department, the NRC or another agreement state. To have its certification process recognized, a specialty board shall require all candidates for certification to have either of the following: